Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 13/20 | 0.61 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | PDE1A | P54750 | 2/20 | 0.56 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.56 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TERT | O14746 | 2/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.50 |
| ▸ | PDE6C | P51160 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7094172 | 0.93 | PDE5A (0.62) | PDE5AMTORKMT2APDE1APDE1B | |
| SCHEMBL31607170 | 0.86 | PDE5A (0.56) | PDE5AMTORKMT2APDE1APDE1B | |
| SCHEMBL3838889 | 0.84 | PDE5A (0.44) | PDE5AMTORKMT2APDE1APDE1B | |
| SCHEMBL3845619 | 0.84 | PDE5A (0.62) | PDE5AMTORKMT2APDE1APDE1B | |
| SCHEMBL3127667 | 0.82 | PDE5A (0.61) | PDE5AMTORKMT2APDE1APDE1B | |
| SCHEMBL7094075 | 0.82 | PDE5A (0.67) | PDE5AMTORKMT2APDE1APDE1B | |
| SCHEMBL7306306 | 0.80 | PDE5A (0.56) | PDE5AMTORKMT2APDE1APDE1B | |
| SCHEMBL7309086 | 0.80 | PDE5A (0.56) | PDE5AMTORKMT2APDE1APDE1B | |
| SCHEMBL7309369 | 0.80 | PDE5A (0.57) | PDE5AMTORKMT2APDE1APDE1B | |
| SCHEMBL7313119 | 0.80 | PDE5A (0.56) | PDE5AMTORKMT2APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1793828-A4 | FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | REDDYS LAB LTD DR (IN) | 2009-09-02 | — | — | EP | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| EP-1793828-A2 | FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | Dr. Reddy's Laboratories Ltd. (IN) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006029075-A2 | FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-03-16 | — | — | WO | disclosed |
| US-20050096331-A1 | Novel compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES INC. | 2005-05-05 | — | — | US | disclosed |
| EP-1363914-A1 | ARYL SUBSTITUTED ALKYLCARBOXYLIC ACIDS AS HYPOCHOLESTEROLEMIC AGENTS | Dr. Reddy's Laboratories Ltd. (IN) | 2003-11-26 | — | — | EP | disclosed |
| WO-2003053974-A1 | NOVEL COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-07-03 | — | — | WO | disclosed |
| US-6444816-B1 | DIETETICS, ANTICHOLESTEROL AGENTS, ANTIDIABETIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2002-09-03 | — | — | US | disclosed |
| WO-2002062799-A1 | ARYL SUBSTITUTED ALKYLCARBOXYLIC ACIDS AS HYPOCHOLESTEROLEMIC AGENTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096331-A1 | Novel compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them | GPR119, LIPA, CETP | PDE5A 1562/4885MTOR 598/4885KMT2A 4570/4885 |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | PPARA, PPARD, PPARG | PDE5A 1657/4885MTOR 1645/4885KMT2A 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.